iRhythm Technologies (IRTC) Competitors

iRhythm Technologies (NASDAQ:IRTC) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Does the media prefer IRTC or ZBH?

In the previous week, Zimmer Biomet had 8 more articles in the media than iRhythm Technologies. MarketBeat recorded 14 mentions for Zimmer Biomet and 6 mentions for iRhythm Technologies. Zimmer Biomet's average media sentiment score of 1.21 beat iRhythm Technologies' score of 0.89 indicating that Zimmer Biomet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zimmer Biomet	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of IRTC or ZBH?

88.9% of Zimmer Biomet shares are owned by institutional investors. 0.7% of iRhythm Technologies shares are owned by company insiders. Comparatively, 0.7% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is IRTC or ZBH more profitable?

Zimmer Biomet has a net margin of 11.86% compared to iRhythm Technologies' net margin of -15.90%. Zimmer Biomet's return on equity of 12.73% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-15.90%	-101.04%	-9.55%
Zimmer Biomet	11.86%	12.73%	7.34%

Do analysts prefer IRTC or ZBH?

iRhythm Technologies currently has a consensus target price of $138.60, suggesting a potential downside of 1.06%. Zimmer Biomet has a consensus target price of $111.33, suggesting a potential upside of 20.34%. Given Zimmer Biomet's higher probable upside, analysts clearly believe Zimmer Biomet is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Zimmer Biomet	2 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.30

Which has more risk & volatility, IRTC or ZBH?

iRhythm Technologies has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500.

Which has stronger valuation and earnings, IRTC or ZBH?

Zimmer Biomet has higher revenue and earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$591.84M	7.56	-$113.29M	-$3.14	-44.61
Zimmer Biomet	$7.68B	2.38	$903.70M	$4.52	20.47

Summary

Zimmer Biomet beats iRhythm Technologies on 12 of the 16 factors compared between the two stocks.